PTGX – Protagonist Therapeutics Inc
PTGX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
12.45
Margin Of Safety %
Put/Call OI Ratio
1.68
EPS Next Q Diff
0.53
EPS Last/This Y
4.7
EPS This/Next Y
-3.49
Price
99.97
Target Price
116.69
Analyst Recom
1.23
Performance Q
19.16
Upside
-123.4%
Beta
1.88
Ticker: PTGX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-13 | PTGX | 97.55 | 0.41 | 0.33 | 7412 |
| 2026-04-14 | PTGX | 104.8 | 0.40 | 0.09 | 7385 |
| 2026-04-15 | PTGX | 105.39 | 0.44 | 0.30 | 7051 |
| 2026-04-20 | PTGX | 105.33 | 0.72 | 0.03 | 3140 |
| 2026-04-23 | PTGX | 102.63 | 0.70 | 0.19 | 3244 |
| 2026-04-24 | PTGX | 99.83 | 0.69 | 4.70 | 3269 |
| 2026-04-27 | PTGX | 98.33 | 0.72 | 35.87 | 3322 |
| 2026-04-28 | PTGX | 101.29 | 1.03 | 0.05 | 3951 |
| 2026-04-29 | PTGX | 98.57 | 1.48 | 0.38 | 4863 |
| 2026-04-30 | PTGX | 98.89 | 1.48 | 10.00 | 4872 |
| 2026-05-01 | PTGX | 98.22 | 1.48 | 0.00 | 4882 |
| 2026-05-04 | PTGX | 99.54 | 1.48 | 0.00 | 4880 |
| 2026-05-05 | PTGX | 99.16 | 1.48 | 0.00 | 4881 |
| 2026-05-06 | PTGX | 104.1 | 1.48 | 2.88 | 4885 |
| 2026-05-07 | PTGX | 98.8 | 1.47 | 0.50 | 4942 |
| 2026-05-08 | PTGX | 99.36 | 1.47 | 0.00 | 4950 |
| 2026-05-11 | PTGX | 103.58 | 1.48 | 26.73 | 4935 |
| 2026-05-12 | PTGX | 100.04 | 1.68 | 0.00 | 5322 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-13 | PTGX | 97.54 | -244.3 | - | 2.77 |
| 2026-04-14 | PTGX | 104.69 | -244.3 | - | 2.77 |
| 2026-04-15 | PTGX | 105.44 | -244.3 | - | 2.77 |
| 2026-04-16 | PTGX | 103.78 | -244.3 | - | 2.77 |
| 2026-04-17 | PTGX | 106.05 | -244.3 | - | 2.77 |
| 2026-04-20 | PTGX | 105.43 | -244.3 | - | 2.77 |
| 2026-04-21 | PTGX | 105.91 | -244.3 | - | 2.77 |
| 2026-04-22 | PTGX | 105.56 | -244.3 | - | 2.77 |
| 2026-04-23 | PTGX | 102.55 | -244.3 | - | 2.77 |
| 2026-04-24 | PTGX | 100.00 | -244.3 | - | 2.77 |
| 2026-04-27 | PTGX | 98.43 | -244.3 | - | 2.77 |
| 2026-04-28 | PTGX | 101.12 | -244.3 | - | 2.77 |
| 2026-04-30 | PTGX | 98.91 | -244.3 | - | 2.77 |
| 2026-05-01 | PTGX | 98.28 | -244.3 | - | 2.77 |
| 2026-05-04 | PTGX | 99.54 | -244.3 | - | 2.77 |
| 2026-05-05 | PTGX | 99.19 | -244.3 | - | 2.77 |
| 2026-05-06 | PTGX | 104.00 | -244.3 | - | 2.77 |
| 2026-05-07 | PTGX | 98.85 | -244.3 | - | 2.77 |
| 2026-05-08 | PTGX | 99.25 | 356.0 | - | 2.65 |
| 2026-05-11 | PTGX | 103.51 | 356.0 | - | 2.65 |
| 2026-05-12 | PTGX | 99.97 | 431.3 | - | 2.65 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-13 | PTGX | -8.20 | 2.03 | 14.38 |
| 2026-04-14 | PTGX | -8.20 | 2.03 | 14.38 |
| 2026-04-15 | PTGX | -7.93 | 2.03 | 14.38 |
| 2026-04-16 | PTGX | -7.93 | 2.03 | 14.38 |
| 2026-04-17 | PTGX | -7.93 | 2.03 | 14.38 |
| 2026-04-20 | PTGX | -7.93 | 2.06 | 14.38 |
| 2026-04-21 | PTGX | -7.97 | 2.06 | 14.38 |
| 2026-04-22 | PTGX | -7.97 | 2.06 | 14.38 |
| 2026-04-23 | PTGX | -7.97 | 2.06 | 14.38 |
| 2026-04-24 | PTGX | -7.97 | 2.06 | 14.38 |
| 2026-04-27 | PTGX | -7.97 | 2.68 | 13.97 |
| 2026-04-28 | PTGX | -8.22 | 2.68 | 13.97 |
| 2026-04-29 | PTGX | -8.22 | 2.68 | 13.97 |
| 2026-04-30 | PTGX | -8.22 | 2.68 | 13.97 |
| 2026-05-01 | PTGX | -8.22 | 2.68 | 13.97 |
| 2026-05-04 | PTGX | -8.22 | 2.51 | 13.97 |
| 2026-05-05 | PTGX | -8.22 | 2.51 | 13.97 |
| 2026-05-06 | PTGX | -8.22 | 2.51 | 13.97 |
| 2026-05-07 | PTGX | -8.22 | 2.51 | 13.97 |
| 2026-05-08 | PTGX | -8.17 | 2.51 | 13.86 |
| 2026-05-11 | PTGX | -8.17 | 3.34 | 13.86 |
| 2026-05-12 | PTGX | -9.49 | 3.34 | 12.45 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.05
Avg. EPS Est. Current Quarter
1.82
Avg. EPS Est. Next Quarter
0.58
Insider Transactions
-9.49
Institutional Transactions
3.34
Beta
1.88
Average Sales Estimate Current Quarter
186
Average Sales Estimate Next Quarter
172
Fair Value
Quality Score
26
Growth Score
29
Sentiment Score
79
Actual DrawDown %
7.3
Max Drawdown 5-Year %
-85.8
Target Price
116.69
P/E
Forward P/E
PEG
P/S
86.79
P/B
9.79
P/Free Cash Flow
EPS
-1.8
Average EPS Est. Cur. Y
2.65
EPS Next Y. (Est.)
-0.84
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
-154.88
Relative Volume
0.86
Return on Equity vs Sector %
-44.4
Return on Equity vs Industry %
-28.8
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.13
EBIT Estimation
◆
PTGX
Healthcare
$99.95
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
48.8
Range 1M
27%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
291.1%
EPS NY
-128.2%
52W%
85.6%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+16.7% upside
Upside
+16.7%
Quality
26
Protagonist Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 131
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
PTGX
Latest News
—
Caricamento notizie per PTGX…
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading